Sangamo Biosciences (SGMO) has disclosed a new risk, in the Competition category.
Sangamo Biosciences faces significant business risks in the highly competitive field of biotechnology and genomic medicine. Numerous competitors, including biopharmaceutical companies, academic institutions, and government agencies, are rapidly advancing in gene editing and therapy technologies, some of which may surpass or be commercialized more swiftly than Sangamo’s offerings. This intense competition, characterized by substantial capital resources and extensive research capabilities, could limit Sangamo’s market opportunities, particularly if rival technologies prove to be more effective or cost-efficient. Furthermore, the challenge of attracting qualified personnel and securing strategic collaborations adds to the risk, as competitors may succeed in patenting and launching products ahead of Sangamo, potentially undermining its market position.
The average SGMO stock price target is $5.00, implying 490.95% upside potential.
To learn more about Sangamo Biosciences’ risk factors, click here.